A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2015
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Registrational; Therapeutic Use
- Acronyms RESET
- Sponsors Vanda Pharmaceuticals
- 06 Aug 2015 Results of two trials (SET and RESET) published online in the Lancet.
- 05 Aug 2015 According to a Vanda Pharmaceuticals media release, this and SET trial led to approval with the European marketing authorization for Hetlioz.
- 05 Aug 2015 Results published in the Vanda Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History